Matthew Collinson-Pautz
Company: Indapta Therapeutics
Job title: Director - Preclinical & Translational Research
Seminars:
Chair’s Opening Remarks 8:25 am
day: Day 1 AM
Industry Leader’s Fireside Chat: Discussing Present Advancements & Challenges in the Natural Killer Space to Envision the Future of NK Therapy 8:30 am
Discussing key advancements in the NK space to highlight the therapeutic potential of NK biology Sharing the latest findings in NK therapy and what this means for this field What are the biggest hurdles in this space that still need to be overcome?Read more
day: Day 1 AM
Chair’s Opening Remarks 8:55 am
day: Pre-Conference Focus Day
Roundtable Discussion: Discussing the Persistence of NK Cells in an Autoimmune Context 11:00 am
Is short lived persistence advantageous in an autoimmune setting as opposed to oncology? Evaluating if NKs are efficacious in eradicating autoimmune cells and whether patients need re-dosing Based on our understanding of NK biology can we predict what long term outcomes would look like in autoimmune patients?Read more
day: Pre-Conference Focus Day
Panel Discussion: Evaluating NK Treatment Regiments in Autoimmune Patients to Maximize Treatment Outcomes 3:15 pm
Discussing patient treatment regiments and pre-treatment procedures in an autoimmune setting Do the same measures such as lymphodepletion need to be applied to autoimmune patients? What dosing regiment may be most beneficial for autoimmune patients? Is it feasible to dose autoimmune patients several times?Read more
day: Pre-Conference Focus Day